BioStem Technologies, Inc. Common Stock H.C. Wainwright 28th Annual Global Investment Conference

Thanks so much, RK. Really appreciate you guys having us here on this fireside chat.

Yeah. First and foremost, it was definitely a lot of hard work and a huge thank you and congratulations to the rest of our team. Their dedication to getting through a lot of the processes, along with meeting with the SEC and Nasdaq uplisting requirements, as well as the audit work that you just mentioned. A substantial portion of that work was focused on 2023 and 2024-- excuse me, 2024 and 2025 audits. As many of the investors have seen, we did a restatement of those financials and adopted a new revenue recognition methodology based on how we were transacting with our distributor partner at the time, Venture Medical, and our end customer. That didn't really change anything in regards to profitability or cash generation side of the business, or on the P&L, or the balance sheet. It was just more about rev rec.

We've gotten through that and put that to the past, and we're looking forward to this year and the years to come being listed on the Nasdaq.

Yeah, I think all of the above. We're really excited about being listed on the Nasdaq, and there's a significant amount of advantages for a business like ours to be listed on Nasdaq. All the benefits that you mentioned. Importantly, we are excited about what this really means for the visibility of our brand and our brand nationally and the increased ability to recruit and retain top talent, and folks on our team who can help commercialize the products, manufacture the products, and hopefully develop new products.

Yeah. We really looked at this transaction as a strategic pivot, as you mentioned earlier in the introduction, really moving our business from the wound care physician office market into the surgical setting. BioTissue really developed a really strong portfolio of products, and we view that as being differentiated in the market and also complementary with our existing products, meaning that all of them are in the perinatal tissue space, so umbilical cord tissue, placental-based tissues. They all met the really robust quality and clinical standards, being an AATB-accredited facility like theirs. I think there's a lot of synergies. We also looked at how bringing on, not only is it a transaction of assets in the sense of products, but also a commercial team.

We were able to ingest a lot of the commercial infrastructure and commercial team that we historically didn't have by transacting in the physician office with Venture Medical. We now have initially 15 reps, growing that to 30 W-2 reps, as well as a robust independent sales agents group, as well as the infrastructure to support from a billing and everything else in regards to supporting those folks in the field.

I think we maybe focus ourselves as more of a regenerative medicine company supporting healing in surgical applications across the body itself. Key areas that we really started to focus on is urology and women's health. All of the aggregate applications that we talk about in our presentation, that TAM kind of addresses roughly about $26 billion in market. I want to actually go back to your original question about maybe what BioTissue didn't see in the business that we had an opportunity to do. BioTissue wanted to focus on their ocular franchise as well. Us being able to acquire that surgical wound care business away from them allowed them to really focus on singular, their ocular franchise and take on a business where they were just really managing it for cash and not really managing it for investment of growth.

We feel, as we acquired the business, rolled it into our organization, there's a great opportunity to grow that business as well.